The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | Incorporating MRD assessment into clinical decision-making in AML: recent ELN guideline update
In this video, Francesco Buccisano, MD, University of Rome Tor Vergata, Rome, Italy, provides insight into the recently updated European LeukemiaNet (ELN) guidelines for incorporating measurable residual disease (MRD) assessment into clinical decision-making in acute myeloid leukemia (AML). He highlights that there is a most appropriate tool for measuring MRD in each AML subset, meaning that MRD assessment should be tailored where possible. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is exactly the philosophy of the recent update of the ELN-DAVID MRD guidelines for AML. We decided to link every MRD assessment at some specific time point to a signal that is coded by alert warning or green light that is exactly directed to the physician to make it easier to interpret the value of MRD in terms of a decision making algorithm. So my suggestion is to follow our last version of the guidelines because it’s exactly set on this kind of communication with physicians...
This is exactly the philosophy of the recent update of the ELN-DAVID MRD guidelines for AML. We decided to link every MRD assessment at some specific time point to a signal that is coded by alert warning or green light that is exactly directed to the physician to make it easier to interpret the value of MRD in terms of a decision making algorithm. So my suggestion is to follow our last version of the guidelines because it’s exactly set on this kind of communication with physicians. In general, every subset of AML has its own most appropriate tool to measure MRD. For instance, among favorable core binding factor mutated patients, RT-qPCR, so quantitative polymerase chain reaction assessment, is the most validated. For those patients without a specific genetic signature, immunophenotype multi-parameter flow cytometry is a validated tool. And the novelty in the new guidelines of the ELN group is the possibility to study some mutations like FLT3-ITD by ultra-sensitive NGS and this is probably a very useful tool that is not available in every center. So we have provided a plan B for every subset of leukemia. So in this case you can use immunophenotype but you know things are improving also for these more complicated techniques.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Jazz, Menarini, Servier
